The forecasted sales of Genito Urinary System and Sex Hormones in Italy indicate a steady decline from a value of 1.4 in 2024 to 1.1 by 2028. Compared to the 2023 figures, this suggests an increasingly decreasing trend. Between 2024 and 2028, year-on-year variations indicate a gradual reduction annually, with a visible decline in 2028. Consequently, the compound annual growth rate (CAGR) over this period also reflects a consistent downturn.
Future trends to watch for include:
- Emerging innovations in treatment that may impact sales positively.
- Changes in regulatory practices affecting market dynamics.
- Demographic shifts potentially influencing demand for these medications.
- Entrance of generics or new competitors could further pressure market values.
